D3 Bio, a global, clinical-stage biotech company that counts Singapore’s Temasek Holdings and Boyu Capital among its investors, has closed a $62-million Series A+ round of financing to advance its pipeline of cancer drugs.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
